Government Move to Rein in Prices of Expensive Cancer Drugs

The Union government has decided to cap trade margins on around 110 expensive cancer medicines, including nearly 35 patented drugs.The measure is expected to reduce the market prices of selected cancer medicines by up to 70%.

Why is Price Regulation Needed?

• India’s cancer burden is rising, while newer targeted therapies and immunotherapies remain extremely expensive.
• A Tata Memorial Hospital study found that only about 1.6% of eligible patients could access immunotherapy, with cost being a major barrier.
• The Supreme Court has also raised concerns over very high mark-ups on certain cancer drugs.

What is Trade Margin Rationalisation (TMR)?

• Trade margin is the difference between the price at which a medicine is first sold to stockists and its final Maximum Retail Price (MRP).
• Under TMR, instead of fixing the price of every formulation or brand, the government caps the percentage mark-up allowed in the distribution chain.
• This seeks to reduce excessive margins while maintaining supply and commercial viability.

Which Drugs Are Likely to be Covered?

• The list is expected to include branded, generic, imported and domestically manufactured cancer medicines.
• Priority will be given to expensive and commonly used cancer drugs.
• The government is considering medicines that have been widely used in cancer treatment for several years.

How Does the Government Regulate Drug Prices?

• The National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for scheduled drugs listed in the National List of Essential Medicines (NLEM).
• For non-scheduled medicines, companies generally cannot increase MRP by more than 10% in a year.
• Trade Margin Rationalisation is aimed particularly at expensive non-scheduled cancer medicines, where mark-ups can be very high.

How Much Could Prices Fall?

• NPPA estimates suggest non-scheduled anti-cancer medicines have an average trade mark-up of about 170%, reaching up to 700% in some cases.
• Experts estimate TMR could reduce MRPs by roughly 20–70%.
• The move could potentially generate annual savings of around ₹2,500 crore for patients.

Key Challenges

• Companies may use practices such as free units or commercial discounts to preserve high effective margins despite formal caps.
• Experts argue that price ceilings should also consider the actual manufacturing or import cost.
• Patented medicines may remain expensive because they face limited competition.
• Previous margin controls have not always prevented price increases in some patented cancer drugs.

The government’s strategy focuses on reducing excessive distribution mark-ups rather than directly fixing every cancer-drug price, but affordability of patented medicines may still require stronger competition and cost-based regulation.